ESC 365 - Will the availability of specific reversal agents change the use of NOACs?

ESC Premium Access

Will the availability of specific reversal agents change the use of NOACs?

Session: Reversal of NOACs' effect: when and how?

Topic: Drug therapy

Speaker: Professor F. Verheugt (Amsterdam, NL)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor Freek Verheugt

Hospital Onze Lieve Vrouwe Gasthuis, Amsterdam (Netherlands (The))

22 presentations

0 follower

3 more presentations in this session

When should I use reversal agents for NOACs?

Speaker: Professor G. Lip (Liverpool, GB)

Reversal of the thrombin inhibitor dabigatran.

Speaker: Professor A. Niessner (Vienna, AT)

Reversal of FXa inhibitors.

Speaker: Associate Professor S. Wassmann (Munich, DE)

Access the full session

Reversal of NOACs' effect: when and how?

Speakers: Professor F. Verheugt, Professor G. Lip, Professor A. Niessner, Associate Professor S. Wassmann

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources